OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
The companies will collaborate at BioCentriq’s GMP facilities to produce Tevogen’s proprietary COVID-19 targeted T cells.
Tevogen Bio, a clinical stage biotechnology company, announced on March 15, 2021 that it has entered into a partnership with BioCentriq, a cell and gene therapy development and manufacturing center, to support clinical manufacturing of Tevogen’s investigational T-cell therapy COVID-19 treatment.
Under the terms of the agreement, the companies will collaborate at BioCentriq’s GMP facilities to produce Tevogen’s proprietary COVID-19 targeted T cells, Tevogen said in a company press release. Currently, an Investigational New Drug application for the T-cell therapy is being reviewed by FDA.
“T-cell therapies are the next frontier of medicine, and we are thrilled to partner with such a prestigious research institute at the forefront of cell and gene therapy to support our mission to create affordable and scalable curative therapies,” said Ryan Saadi, MD, chairman and CEO of Tevogen, in the press release.